T2 Biosystems, Inc. (TTOO) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, everyone, and welcome to the T2 Biosystems, Inc. Business Update Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, Tripp Taylor. Sir, the floor is yours. Thank you, Operator. I'd like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems' future financial and operating results and plans for developing and marketing new products. Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by these statements, including the risks and uncertainties described in T2 Biosystems' annual report on Form 10-K filed with the SEC on April 1, 2024, and other filings the company makes with the SEC from time to time. The company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law. With that, I would like to turn the call over to Chairman and CEO, John Spurzel. John? Thank you for joining our investor call. The purpose of today's call is to discuss a number of recent developments that we believe can be transformative for T2 Biosystems. In advance of this call, we solicited questions from investors and we have incorporated our responses to those questions in today's script. While I will focus my comments on our core sepsis business, I will also address two additional business opportunities, bioterrorism and Lyme disease. Let's start with a brief description of sepsis and an overview of our ...